Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 932-231-6 | CAS number: 1335202-81-7
Endpoint summary
Administrative data
Description of key information
The acute toxicity of CaDDBS via oral exposures was tested in rats. The acute dermal toxicity of the analogue NaLAS was also tested in rats. No acute toxicity was observed at doses exceeding the maximum limit doses for both the oral or dermal exposures. Therefore, CaDDBS is not classified either under the DSD or the CLP.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Dose descriptor:
- LD50
- Value:
- 4 445 mg/kg bw
Acute toxicity: via dermal route
Endpoint conclusion
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
Groups of 10 female rats were exposed by oral gavage to doses of 2500, 3200, 5000, and 6300 mg/kg of calcium dodecylbenzene sulphonate. The animals were then monitored for the 14 days for mortality, and weighed weekly. The LD50 was determined to be 4445 mg/kg. Surviving animals showed no effects. Dermal toxicity was examined for the sodium salt of LAS. The clipped skin on the backs of five male and five female rats were exposed to LAS under an occlusive dressing for 24 hours and observed for another 14 days. Results indicate slight erythema and slight oedema but no acute mortality. The dermal LD50 is > 2000 mg/kg. Based on these results it is concluded that calcium dodecylbenzene sulphonate is not acute toxic via either oral or dermal exposures at doses exceeding the limit doses.
Justification for classification or non-classification
No acute toxicity was observed at doses exceeding the limit doses for oral or dermal exposures. Therefore, CaDDBS is not classified either under the DSD or the CLP.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
